FDA Approves ACTONEL — Allergan, Inc.

# FDA Approves Allergan's ACTONEL (Risedronate Sodium) for Oral Administration Allergan, Inc. has received FDA approval for ACTONEL (risedronate sodium hemipentahydrate), an oral bisphosphonate treatment that is expected to capture significant market share in the osteoporosis segment by offering patients a convenient once-weekly dosing alternative to existing therapies. The approval positions Allergan to compete directly with established bone-health treatments and expand its pharmaceutical portfolio beyond its core specialty care business.